Two years’ experience with denosumab for children with Osteogenesis imperfecta type VI by unknown
Hoyer-Kuhn et al. Orphanet Journal of Rare Diseases 2014, 9:145
http://www.ojrd.com/content/9/1/145RESEARCH Open AccessTwo years’ experience with denosumab for
children with Osteogenesis imperfecta type VI
Heike Hoyer-Kuhn1*, Christian Netzer2, Friederike Koerber3, Eckhard Schoenau1 and Oliver Semler1Abstract
Background: Osteogenesis imperfecta (OI) is a hereditary disease causing reduced bone mass, increased fracture
rate, long bone deformities and vertebral compressions. Additional non skeletal findings are caused by impaired
collagen function and include hyperlaxity of joints and blue sclera. Most OI cases are caused by dominant
mutations in COL1A1/2 affecting bone formation. During the last years, recessive forms of OI have been identified,
mostly affecting posttranslational modification of collagen. In 2011, mutations in SERPINF1 were identified as the
molecular cause of OI type VI, and thereby a novel pathophysiology of the disease was elucidated. The subgroup of
patients with OI type VI are affected by an increased bone resorption, leading to the same symptoms as observed
in patients with an impaired bone formation. Severely affected children are currently treated with intravenous
bisphosphonates regardless of the underlying mutation and pathophysiology. Patients with OI type VI are known to
have a poor response to such a bisphosphonate treatment.
Method: Deciphering the genetic cause of OI type VI in our 4 patients (three children and one adolescent) led to
an immediate translational approach in the form of a treatment with the monoclonal RANKL antibody Denosumab
(1 mg/kg body weight every 12 weeks).
Results: Short-term biochemical response to this treatment was reported previously. We now present the results
after 2 years of treatment and demonstrate a long term benefit as well as an increase of bone mineral density, a
normalization of vertebral shape, an increase of mobility, and a reduced fracture rate.
Conclusion: This report presents the first two-year data of denosumab treatment in patients with Osteogenesis
imperfecta type VI and in Osteogenesis imperfecta in general as an effective and apparently safe treatment option.
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Osteogenesis imperfecta (OI) is a genetically heterogeneous
hereditary disease characterized by reduced bone mass,
increased fracture rate, vertebral collapses and deformities
of long bones. Non-skeletal findings, e.g., dentinogenesis
imperfecta, blue sclera, or hyperlaxity of ligaments, can be
associated. Dominant mutations in COL1A1 or COL1A2
that lead to a quantitative or a qualitative defect in collagen
type I are the molecular cause in the majority of patients
[1]. Severely affected individuals are treated with intraven-
ous bisphosphonates regardless of the underlying genetic
cause [2,3].* Correspondence: heike-katharina.hoyer-kuhn@uk-koeln.de
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article, unless otherwise stated.Osteogenesis imperfecta type VI (OI VI) is autosomal-
recessively inherited and displays an increased amount of
non-mineralized osteoid and a poor response to bisphos-
phonate treatment [4,5]. Additional signs are the only
discrete findings at birth and the late onset of fractures and
deformities. OI VI is caused by mutations in SERPINF1, a
gene which is coding for the pigment epithelium-derived
factor (PEDF) [6,7]. In patients with bi-allelic truncating
mutations in SERPINF1, PEDF is not detectable in the
serum [8]. In-vitro and in-vivo models provided evidence
that PEDF inhibits osteoclast differentiation and hence
bone resorption via osteoprotegerin (OPG) and RANKL
[9]. Receptor activator of NF-kB (RANK), the ligand
RANKL, and the decoy receptor OPG are pivotal regulators
of osteoclast differentiation and function. Denosumab is a
monoclonal RANKL-blocking antibody which inhibitsntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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bone mass. It has been approved for the treatment of
postmenopausal osteoporosis in 2010 and of giant cell
tumors of the bone in 2013 [10,11].
We report the first 2-year results of four patients with
genetically confirmed OI VI treated with denosumab.
Understanding the different pathogenesis had encour-
aged us to target the RANK/RANKL pathway directly
with this RANKL antibody as an individual transla-
tional therapeutic approach. Preliminary data of these
four patients on biochemical bone turn-over markers in
the course of a maximum of three treatment cycles
have recently been published by our group [12]. To our
knowledge, these new data about a two years’ experi-
ence are the first about denosumab treatment, side
effects and efficacy determined by changes of the areal
bone mineral density (aBMD) and vertebral morphom-
etry in children with Osteogenesis imperfecta.
Patient
The boys were born to three different consanguineous
couples and presented with a severe phenotype of OI VI
[4]. The clinical findings and clinical courses have been
described in the former publication [12]. OI had been di-
agnosed clinically when the first fractures had occurred.
Spine X-rays had revealed multiple vertebral fractures
and deformities. A therapy with intravenous bisphospho-
nates had been started as described [12]. During bis-
phosphonate therapy treatment response was poor. All
children were depending on a wheelchair. In these pa-
tients, we had identified the causal SERPINF1 mutations
and had discovered the genetic cause of OI VI in the
course of a previous research project [6]. Additionally,
Osteoprotegerin levels as an osteoclastogenesis inhibi-
tory factor were analyzed in two of these patients and
showed reduced values (3.0; 4.0 pmol/l [normal range
5.7 ± 0.42 pmol/l]).
Informed consent was obtained according to the Dec-
laration of Helsinki and an individual translational
therapeutic approach with the RANKL antibody deno-
sumab (Prolia®, Amgen, Thousand Oaks) was started.
Denosumab was injected subcutaneously with a dose of
1 mg per kg body weight. Oral supplementation with
calcium (body weight ≥15 kg: 1000 mg per day; body
weight ≤ 15 kg: 500 mg per day) was administered for
2 weeks after each injection. Additionally, vitamin D
(body weight ≤ 30 kg: 500 international units per day;
body weight ≥30 kg: 1000 international units per day)
was prescribed in all patients because they were vitamin D
depleted. Initially, treatment intervals were 12 weeks.
These intervals were chosen according to the intervals
used in adults [13]. After one year of treatment all
patients were assigned to shorter intervals (minimum 10-
week ) based on the recurrence of skeletal pain and on theincrease of osteoclastic activity 8 weeks after injection
measured by urinary deoxypyridinoline levels/creatinine
(DPD) (data not shown).Methods
Dual-energy X-ray absorptiometry was performed at
the lumbar spine (L2–L4) and for the total body
(excluding the head) using a GE Lunar iDXA densitom-
eter (GE Ultraschall GmbH, Solingen, Germany) and
Encore software version 13.6. Areal BMD results were
transformed to age-specific z-scores using reference
data provided by the company [14].
We used urinary deoxypyridinoline/creatinine ratio
(DPD/crea) to quantify and monitor the inhibition of
bone resorption. Urinary concentrations of DPD were
measured with a commercially available chemilumines-
cence assay (Pyrilinks®-D, Siemens Medical Solutions
Diagnostics). The DPD/crea ratio was compared to age-
and sex- matched reference data, as published by our
laboratory [15]. Due to a change of the analytic proce-
dures we had to analyze the later samples with High-
Performance-Liquid-Chromatography with age matched
reference data. Osteocalcin (Enzyme-immuno-Assay,
reference ranges 10-100 ng/ml), Parathyroid hormone
(Modular E-Modul, Roche Diagnostics, Germany, reference
range 12–72 ng/l), 25-OH Vitamin D Modular E-Modul,
Roche Diagnostics, Germany, reference range 30–70 μg/l)
and total serum Calcium (Modular P-Modul, Roche Diag-
nostics, Germany, reference range 2.2-2.65 mmol/l)
were measured in the serum by our university central
laboratory.
Lateral x-rays of the spine were taken routinely. Spine
morphometry was evaluated based on the semiquantita-
tive score described by Koerber et al. assessing vertebral
compression and deformity [16]. They were evaluated by
the same radiologist. Additionally, calculation of the
projected vertebral area of the lumbar vertebrae (L2-L4)
was performed as described recently [17].
Mobility was assessed using the Gross Motor Function
Measure (GMFM66) [18] and the Brief Assessment of
Motor Function (BAMF) [19].Results
After two years of treatment all 4 patients were in a
stable clinical condition. There was no treatment inter-
ruption based on unexpected side effects. Especially no
signs of allergic reactions or clinical significant hypocal-
cemia have been reported. Patients 3 and 4 reported in
the previous publication intermittently went back to
their mother country for nearly one year. Therefore
results of mobility and data of one year follow up were
presented in detail only for patient 1 and 2.
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A synopsis of the clinical data and clinical course is
given in Table 1. In three children, body length increased
during denosumab treatment. One patient reached his
final height before starting denosumab. Two patients
suffered two fractures during the follow-up period due
to mild traumata.
Areal bone mineral density
Areal bone mineral density was assessed once a year.
In all subjects, a continuous increase of aBMD was seen
after one and two years of denosumab treatment. Age-
matched z-scores and absolute values of patient 1 and 2
are presented graphically in Figure 1. In patient 3 and 4
aBMD (total body less head) changed from 0.373 g/cm2
(z-score −2.9) to 0.407 g/cm2 (z-score −2.9) and from
0.59 g/cm2 (z-score −2.8) to 0.633 g/cm2 (z-score −2.6),
respectively at the only follow up visit after two years.
Desoxypyridinoline level
A decrease of DPD excretion after denosumab injections
into the reference range could be observed repeatedly.
Data are presented exemplarily in Table 2 [15].
Spine morphology
Changes of spine morphology of patient 1 and 2 during
denosumab treatment in the lateral spine x-rays are pre-
sented in Figure 1. The vertebrae showed a re-shape
phenomenon in both patients. A standardized assess-
ment of the spine morphology revealed a stabilizationTable 1 Clinical characteristics at the start and during denosu
Findings Patient 1
Mutation in SERPINF1 c.324_325
Duration of previous bisphosphonate treatment [years] 8.1
Age at start of denosumab therapy [years] 9.4
Time since first denosumab injection [years] 2.4
Number of denosumab treatment cycles [n] 12
Length [cm] (SD) at start 109 (−4.0)
Length [cm] (SD) after two years 117 (−3.7)
Weight [kg] / BMI [kg/m2] at start 19.7/16.6
Weight [kg] / BMI [kg/m2] after two years 28.2/20.6
BAMF mobility score at start 3
BAMF mobility score after one year 3
BAMF mobility score after two years 4
GMFM 66 score at start 32.31
GMFM 66 score after one year 31.78
GMFM 66 score after two years 34.37
Fractures under denosumab treatment [n] 2
Abbreviations: BMI: Body Mass Index, BAMF: Brief Assessment of Motor Function, GMand/or improvement in both children. The score levels
are presented in Figure 1. Additionally, morphometric
parameters are presented in Figure 1, showing an
increase of the complete lumbar vertebral area of L2-L4.
Mobility
The GMFM ranks showed stable results in both patients
1 and 2. GMFM 66 scores are presented in Table 1. The
patients were not able to stand, walk, or jump, but at
least mobility scores did not decrease further.
BAMF was additionally assessed every year and
showed a slight increase after two years of denosumab
treatment in all patients (Table 1).
Safety
No severe side effects were reported by our 4 patients.
All injections were well tolerated without any changes
in vital signs. Serum calcium concentrations decreased
repeatedly, and serum parathyroid hormone levels
increased slightly (Table 3). There was no secondary
hyperparathyreoidism observed over the whole period
of two years. The slight hypocalcaemia after each
injection could be compensated by oral calcium sup-
plementation (lowest ionisized serum calcium level
was 0.96 mmol/l, lowest total serum calcium level
1.97 mmol/l). Osteocalcin levels as a marker for bone
formation stayed in the age related normal range in all
patients (Table 3). No increased rate of infections was
observed. Two patients suffered two fractures during
the follow-up period due to mild trauma. The 3mab treatment
Patient 2 Patient 3 Patient 4





102 (−3.55) 89 (−5.8) 120 (−9.9)










FM: Gross Motor Function Measurement.
Figure 1 Changes of areal bone mineral density, vertebral morphology and morphometry within the two years of treatment with
denosumab in patient 1 and 2. At the top, lumbar spine radiograms of patient 1 and 2 are presented at start and after 2 years of denosumab
treatment showing a re-shaping of the vertebrae in both patients. In the middle, changes of lumbar areal bone mineral density at the starting point of
the observation and after one and two years of therapy are presented graphically. At the bottom, data of the lumbar and total bone mineral density
display an increase in both patients. Additionally, data of the spine score (vertebral compression and deformity) and projected vertebral area of lumbar
vertebrae 2–4 demonstrate an improvement in both patients. Abbreviations: BMD L2-L4: areal bone mineral density of the lumbar vertebrae 2–4.
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of treatment showed an increase of body length dur-
ing the treatment period of 8 cm, 5 cm and 6 cm,
respectively.Discussion
Efficacy
Measurements of urinary DPD showed a suppression of
bone resorption after denosumab application, and
Table 2 Changes of urinary deoxypyridinoline excretion during denosumab treatment
Urinary deoxypyridinoline/creatinine ratio (age related normal range)
Patient 1 Patient 2 Patient 3 Patient 4
Days after injection 1st Cycle 1st Cycle 1st Cycle 1st Cycle
Day 1 44 (6.5-26.5 nM/mM) 32 (6.5-26.5 nM/mM) 82 (6.5-26.5 nM/mM) 41 (0.0-17.8 nM/mM)
Day 14 14 (6.5-26.5 nM/mM) 25 (6.5-26.5 nM/mM) 26 (6.5-26.5 nM/mM) 20 (0.0-17.8 nM/mM)
Day 28 25 (6.5-26.5 nM/mM) 13 (6.5-26.5 nM/mM) 25 (6.5-26.5 nM/mM) 17 (0.0-17.8 nM/mM)
3rd Cycle 4th Cycle 8th Cycle 8th Cycle
Day 1 48 (6.5-26.5 nM/mM) 78 (6.5-26.5 nM/mM) 620 (110–450 μg/g) 83 (10–50 μg/g)
Day 14 10 (6.5-26.5 nM/mM) 24 (6.5-26.5 nM/mM) 133 (110–450 μg/g) 50 (10–50 μg/g)
Day 28 32 (6.5-26.5 nM/mM) 19 (6.5-26.5 nM/mM) 431* (110–450 μg/g) 23 (10–50 μg/g)
7th Cycle 10th Cycle - -
Day 1 42 (6.5-26.5 nM/mM) 477 (110–450 μg/g) - -
Day 14 28 (6.5-26.5 nM/mM) 110 (110–450 μg/g) - -
Day 28 19 (6.5-26.5 nM/mM) 197 (110–450 μg/g) - -
Changes of urinary deoxypyridinoline levels (urinary deoxypyridinoline/creatinine ratio) presented exemplarily for different treatment cycles in all patients. Based
on a change of the method reference ranges differed over the period and for clarity every reference range (as provided by the laboratories) are shown after every
measured DPD level. The results of the first cycle and of previous bisphosphonate therapy have already been described in part [12].
*→ Value 3 days after elective surgery of right femur due to dislocation of intramedullary rod.
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was observed in all patients. These are the major findings
which underline efficacy of the denosumab treatment
(Figure 1; Tables 2 and 3). In general, the clinical course of
all patients improved as reported by the families. It is
known that bisphosphonates are not as effective in children
with OI VI as in children with other types of OI [5]. There-
fore these results are interesting especially because both
agents are “antiresorptive agents”. It might be argued that
the large amount of osteoid which is characteristic for OI
VI is responsible for a reduced efficacy of bisphosphonates.
Bisphosphonates bind on the hydroxylapatites on the bone
surface. Osteoid as the unmineralized compartment of the
bone could not be bound by bisphosphonates and there-
fore the induction of osteoclastic apoptosis by bisphospho-
nates might not be as effective in OI VI as in other types of
OI [5]. Denosumab as a RANKL antibody acts independ-
ently of the mineralization status of the bone, a fact that
raises the possibility that this antiresorptive agent may be
more effective in reducing osteoclast formation, matur-
ation and bone resorption in patients with OI VI. Further
trials are needed to compare the effect of a therapy with
bisphosphonates and denosumab in children with OI.
A detailed analysis of the morphometric parameters of
the radiographs taken from the lateral spine showed an
improvement of the shape of the vertebrae which is essen-
tial for stability. This effect was shown by bisphosphonate
treatment in children with typical OI (mutations in
COL1A1/A2) but was not reported in OI VI [5,17].
The four patients with OI VI were severely affected. In
this context, the clinical course during denosumab treat-
ment was satisfying, as fracture rates decreased in all
patients and mobility scores showed a slight increase.Additionally, patients reported reduced bone pain in the
weeks following each denosumab injections, and a recur-
rence of bone pain at the end of each treatment cycle.
Based on our data no final conclusions about duration
of treatment or frequency of injections can be drawn. It
could be speculated that the treatment should be contin-
ued till the end of growth, similar to the currently used
regime for bisphosphonates. Bone turnover is especially
high during childhood and adolescents, and a strong ef-
fect of an antiresorptive treatment can be expected. A
treatment until the end of puberty might also decrease
the risk of a rebound effect after the end of therapy.
However, these questions have to be answered in further
trials.
Safety
No severe side effects were observed. The observed mild
side effects were those cited in the investigators bro-
chure. The drop of serum calcium, a phenomenon which
can be considered as an indicator for the decreased abil-
ity of osteoclasts to resorb bone and to release calcium,
was easy to correct by oral supplementation and vitamin
D supplementation. A decrease in calcium has also been
reported in osteoporotic adults treated with denosumab
[20] and is a common side effect of antiresorptive
agents. This side effect was even used to treat hypercal-
cemia in 2 children after stem cell transplantation in
osteopetrosis [21]. Intravenous calcium substitution as it
was described in a child with juvenile Paget disease was
not needed [22]. At the end of each treatment cycle no
hypercalcemia as it was reported for other patients
[22,23] was observed in our patients. The previous bis-
phosphonate treatment may have attenuated this
Table 3 Bone metabolism markers in patient 1–4 in the last denosumab treatment cylce
Patient 1 Patient 2 Patient 3 Patient 4
Parameter/day after denosumab injection Day 0 Day 0 14 28 Day 0 14 28 Day 0 14 28
Osteocalcin (age adjusted normal range)
[ng/ml]
24 (10.0-100.0) 45 (10.0-50.0) 40 (10.0-50.0) 21 (9.6-41.0)
Parathyroid hormone (12–72 ng/l) 16 7 40 31 14 22 19 48 45 46
Calcium (2.2-2.65 mmol/l) 2.48 2.48 2.14 2.35 2.39 2.25 2.35 2.37 2.31 2.46
25-OH Vitamin D (30–70 μg/l) 19 15.4 23.2 26.7 8.2 8.8 4.3 12.2 10.8 8.1
Desoxypyridinoline/creatinine (age adjusted
normal range) [μg/g]
600 (110–450) 477 (110–450) 110 (110–450) 197 (110-450 620 (110–450) 133 (110–450) 431* (110–450) 83 (10–50) 50 (10–50) 23 (10–50)
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erature also received bisphosphonates prior to denosu-
mab. Another reason for the absence of hypercalcemia in
our patients might be the supplementation regime for cal-
cium, which we administered for only 2 weeks after the
denosumab injections, compared to a continuous treat-
ment in the patient with paget disease. Additionally, the
differing pathophysiology in patients with OI type VI may
have influenced the effect of denosumab on serum cal-
cium levels.
In our patients no increase of fractures, bone pain and
infections has been reported by the patients and their
parents. No growth arrest was observed. The observed
height velocity was reduced in comparison with healthy
children but was not reduced in comparison to the prior
period under bisphosphonate treatment.
After two years of application, the benefits seem to
overweigh the risks of treatment.
In the long term, denosumab might offer an advan-
tage in different disorders with increased bone resorp-
tion because it completely degrades within 3–6 months
after an injection of 1 mg/kg body weight [24]. Bispho-
sphonates are stored in the bone persistently, a fact
which has led to an ongoing debate about their long-
term safety for children [25].
Limitations
Limitations of this brief report are that only two-year data
for four patients with OI VI were available, a consequence
of the fact that OI VI is extremely rare, with only a few pa-
tients currently known in Germany. This small sample
size limits the conclusions that can be drawn from our
data. No controlled setting is available to compare the pre-
sented effects with bisphosphonate efficacy. Recently, sev-
eral case reports about the short-time use of denosumab
in children with different conditions became available, but
there are no long-term data on the use in children
[21-23,26].
Even though this report underlines that denosumab is
well tolerated, the treatment period of two years is still
too short to predict that it will be safe also in the long-
term course, as e.g. allergic reactions or antibodies tar-
geting denosumab may require time to develop. The pa-
tients have to be monitored longer in order to evaluate
the risk-benefit ratio more precisely.
In conclusion, medium-term treatment with denosumab
seems to be safe. No severe side effects were seen, and no
growth arrest was observed in the presented patients.
Efficacy seems to be superior to earlier bisphosphonate
treatment. Treatment with denosumab led to an increase
of areal bone mineral density and mobility, as well as to a
marked and reversible suppression of bone resorption.
Further controlled trials are needed to assess the long-
term effects in comparison to bisphosphonate treatmentprospectively. Last but not least this report is a striking
example of the fact that a precise molecular diagnosis
can have immediate implications for the therapeutic
regime, and that the period of time required to transfer
new scientific insights from “bench to bedside" can
sometimes be very short – in this case, less than a year.
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